April 2012 Drug Information Update - Pharmacy Benefits ...

More documents

Recommendations

Info

PRENATAL VITAMIN PREPARATIONS VITA-MEDMD ONE RX CAPSULE PRENATAL NO.25/ IRON/ FA #6/ DHA 30-1-200MG New Combination PEDIATRIC VITAMIN PREPARATIONS TRI-VI-FLOR DRPS SP MP PED MV A, C, D3 #38 W- FLUORIDE 0.25 MG/ ML New Combination and Dosage Form PEDIATRIC VITAMIN PREPARATIONS TRI-VI-FLOR DRPS SP MP PED MV A, C, D3 #38 W- FLUORIDE 0.5 MG/ ML New Combination and Dosage Form LOCAL ANESTHETICS LIDOCAINE HCL DISP SYRIN LIDOCAINE HCL/ PF 200MG/ 20ML New Strength GENERAL ANESTHETICS, INHALANT ISOFLURANE INHALATION LIQUID ISOFLURANE 99.9% New Strength GENERAL ANESTHETICS, INJECTABLE MIDAZOLAM HCL – 0.9% NACL IV PLAST. BAG MIDAZOLAM HCL IN 0.9% NACL 0.5 MG/ ML New Dosage Form SEDATIVE-HYPNOTICS, NON- BARBITURATE INTER-MEZZO TAB SUBL ZOLPIDEM TARTRATE 1.75 MG New Strength, Route and Dosage Form SEDATIVE-HYPNOTICS, NON- BARBITURATE INTER-MEZZO TAB SUBL ZOLPIDEM TARTRATE 3.5 MG New Strength, Route and Dosage Form ANALGESICS, NARCOTICS MORPHINE SULFATE – 0.9% NACL PCA SYRIN MORPHINE SULFATE/ 0.9% NACL/ PF 50 MG/ 25 ML New Strength ANALGESICS, NARCOTICS HYDROMORPHONE HCL – NS DISP SYRIN HDROMORPHONE HCL IN 0.9% NACL 0.5 MG/ ML New Dosage Form ANALGESIC, NON- SALICYLATE & BARBITURATE COMB. ORBIVAN CF TABLET BUTALBITAL/ ACETAMINOPHEN 50MG-300MG New Strength SYMPATHOMIMETIC AGENTS PHENYLEPHRINE HCL- NS DISP SYRIN PHENYLEPHRINE HCL/ 0.9% NACL/ PF 20MG/ 50ML New Strength GLUCOCORTICOIDS DEXAMETHASONE NS IV PIGGYBACK DEXAMETHASONE IN 0.9% NACL 20MG/ 50ML New Strength, Route and Dosage Form GLUCOCORTICOIDS DEXAMETHASONE NS IV PIGGYBACK DEXAMETHASONE IN 0.9% NACL 10MG/ 50ML New Strength, Route and Dosage Form TOPICAL LOCAL ANESTHETICS LIDOCAINE TOPICAL OINT LIDOCAINE 5% New Strength TOPICAL ANTI- INFLAMMATORY STEROIDAL AQUA GLYCOLIC HC COMBO. PKG HYDROCORTISONE/ SKIN CLNSR #25 2% New Combination Gruenhaupt, Mark R.Ph. Argus Health Systems, Inc. c2005 Available from: www.argushealth.com [cited March 1, 2012]. 6
Gruenhaupt, Mark R.Ph. Argus Health Systems, Inc. c2005 Available from: www.argushealth.com [cited March 15, 2012]. Gruenhaupt, Mark R.Ph. Argus Health Systems, Inc. c2005 Available from: www.argushealth.com [cited March 29, 2012]. New Indications (Existing Drugs) AVONEX® PEN February 28, 2012 FDA Approves AVONEX® PEN and Dose Titration Regimen Dosing Enhancements May Improve Treatment Experience for Patients Receiving AVONEX® (interferon beta-1a) for Multiple Sclerosis Today Biogen Idec announced that the U.S. Food and Drug Administration (FDA) has approved two separate dosing innovations designed to improve the treatment experience for patients receiving once-aweek AVONEX for relapsing forms of multiple sclerosis (MS). AVONEX PEN, the first intramuscular (IM) autoinjector approved for MS, incorporates a smaller needle and easier administration to help patients reduce anxiety about AVONEX self-injection. A new dose titration regimen, which gradually escalates the dose of AVONEX at treatment initiation, reduces the incidence and severity of flu-like symptoms that can occur at the beginning of therapy. Article link: http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1666473 Source website: http://www.biogenidec.com/ ANGELIQ® (Drospirenone and Estradiol) Tablets February 29, 2012 U.S. FDA Approves Lower Dose Formulation of ANGELIQ® (Drospirenone and Estradiol) Tablets Bayer HealthCare Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a lower dose formulation of ANGELIQ® (drospirenone and estradiol) tablets to treat moderate to severe vasomotor symptoms due to menopause in women who have a uterus. The new formulation contains 0.25 mg drospirenone (drsp)/0.5 mg estradiol (E2) and will be available in the U.S. by prescription shortly. Article link: http://www.prnewswire.com/news-releases/us-fda-approves-lower-dose-formulationofangeliq-drospirenone-and-estradiol-tablets-140935233.html Source website: http://www.prnewswire.com/ NATAZIA March 15, 2012 U.S. FDA approves Natazia as the first combined oral contraceptive to treat heavy menstrual bleeding (HMB) The U.S. Food and Drug Administration (FDA) has approved a new indication for Natazia (estradiol valerate and dienogest) tablets for the treatment of heavy menstrual bleeding (HMB) that is not caused by any diagnosed conditions of the uterus (womb), in women who choose to use a combined oral contraceptive for contraception. Article link: http://press.bayerhealthcare.com/en/press/news-details-page.php/14519/2012-0117 Source website: http://www.bayerhealthcare.com/scripts/pages/en/index.php INTELENCE® March 27, 2012 FDA Approves INTELENCE (etravirine) Tablets for Treatment-Experienced Pediatric Patients with HIV-1, Following Priority Review Janssen Therapeutics, Division of Janssen Products, LP, announced today the U.S. Food and Drug Administration (FDA) has approved INTELENCE® (etravirine) to be administered in combination with other antiretroviral (ARV) medications for treatment of human immunodeficiency virus 1 (HIV-1) in treatment-experienced pediatric patients (6 years to
Page 1 and 2: April 2012 Drug Information Update
Page 3 and 4: First-Time Generics GENERIC DRUG NA
Page 5: GENERAL ANESTHETICS, INJECTABLE MID
Page 9 and 10: Statin Drugs - Drug Safety Communic
Page 11 and 12: Vytorin (ezetimibe/simvastatin) Tab
Page 13 and 14: low blood sugar (hypoglycemia) in p
Page 15 and 16: Some women with depression who beco
Page 17 and 18: Survival increased for all groups o
Page 19 and 20: finding that it also may reduce the
Page 21 and 22: Syringes (2 mL size), Rx only. NDC
Page 23 and 24: Patheon Pharmaceuticals Inc., Cinci
Page 25 and 26: 50-ct. bottles (NDC 0067-6238-50);
Page 27 and 28: PRODUCT (Class II) 1) Ventolin HFA
Page 29 and 30: Lot #: 0693, Exp: 10/2012 RECALLING
Page 31 and 32: 24 (Display case UPC# 3030045074923
Page 33 and 34: CODE Lot # 139961 RECALLING FIRM/MA
Page 35 and 36: Reason for the Shortage • Teva co
Page 37 and 38: Reason for the Shortage • Ben Ven
Page 39 and 40: Products Affected - Description Gan
Page 41 and 42: 37.5 mg/25 mg, 1000 count (NDC 0078
Page 43 and 44: Acyclovir tablets, Major 400 tablet
Page 45 and 46: 500 mg, 100 count (NDC 63304-0726-0
Page 47 and 48: 750 mg tablets, 100 count (NDC 1013
Page 49 and 50: • Bedford Laboratories has multip
Page 51 and 52: Daunorubicin Hydrochloride Injectio
Page 53 and 54: Ciprofloxacin Immediate-Release Tab
Page 55 and 56: • APP had tobramycin 40 mg/mL pre
Page 57 and 58:
• Ben Venue voluntarily suspended
Page 59 and 60:
50 mg/mL, 10 mL vial, package of 10
Page 61 and 62:
2 mL vial, preservative-free (NDC 6
Page 63 and 64:
5 mg single dose vial, package of 1
Page 65 and 66:
20 mL glass ampule, sterile pack (N
Page 67 and 68:
2 mL iSecure syringe (NDC 00406-112
Page 69 and 70:
Lidocaine 0.5% Xylocaine 0.5% injec
Page 71 and 72:
• Teva discontinued all ciproflox
Page 73 and 74:
Nicardipine hydrochloride injection
Page 75 and 76:
Article link: http://www.ashp.org/D
Page 77 and 78:
• Apotex had metformin products u
Page 79:
• Covis purchased all rights to F
show all

April 2012 Drug Information Update - Pharmacy Benefits ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?